Susceptibility to a non-conventional (folding) protease inhibitor of human immunodeficiency virus Type 1 isolates in vitro

Proceedings of the International School of Physics "Enrico Fermi"

Volumn 165, Issue , 2007, Pages 293-299

  Rusconi, S ^a   LoCicero, M ^a   Ferramosca, S ^a   Sirianni, F ^a   Galli, M ^a   Moroni, M ^a   Laface, A E ^b   Cesana, E ^b   Clivio, A ^b   Tiana, G ^b,c   Provasi, D ^b,c   Broglia, R A ^b,c,d  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c INFN SEZIONE DI MILANO   (Italy)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78149444121     PISSN: 0074784X     EISSN: 18798195     Source Type: Conference Proceeding    
DOI: None     Document Type: Conference Paper

References (44)

1. PRESTON B., Reverse transcriptase fidelity and HIV-1 variation, Science, 275 (1997) 228.
2. Gu Z., GAO Q., FAUNT E. A. and WAINBERG A., Possible involvement of cell fusion and viral recombination in generation of human immunodeficiency virus variants that display dual resistance to AZT and 3TC, J. Gen. Virol, 76 (1995) 2601.
3. SRINIVASAN A., YORK D., JANNOUN-NASR R., KALYANARAMAN S., SWAN D., BENSON J., BOHAN C, Luciw P. A., SCHNOLL S., ROBINSON R. A., DESAI S. M. and DEVARE S. C., Generation of hybrid human immunodeficiency virus by homologous recombination, Proc. Natl. Acad. Sci. U.S.A., 86 (1989) 6388.
4. TOTH G. and BORICS A., Flap opening mechanism of HIV-1 protease, J. Mol. Graph. Model., 24 (2006) 465.
5. DAVIS D. A., NEWCOMB F. M., STARKE D. W., OTT D. E., MIEYAL J. M. and YARCHOAN R., Thioltransferase (glutaredoxin) is detected within HIV-1 and can regulate the activity of glutathionylated HIV-1 protease in vitro, J. Biol. Chew., 272 (1997) 25935.
6. DAVIS D. A., NEWCOMB F. M., MOSKOVITZ J., WINGFIELD P. T., STAHL S. J., KAUFMAN J., FALES H. M., LEVINE R. L. and YARCHOAN R., HIV-2 protease is inactivated after oxidation at the dimmer interface and activity can be partly restored with methionine sulphoxide reductase, Biochem. J., 346 (2000) 305.
7. Wu T. D., SCHIFFER C. A., GONZALES M. J., TAYLOR J., KANTOR R. and CHOU S. et al., Mutation pattern and structural correlates in immunodeficiency virus type 1 protease following different protease inhibitor treatments, J. Virol., 77 (2003) 4836.
8. CECCHERINI-SILBERSTEIN F., ERBA F., GAGO F., BERTOLI A., FORBICI F., BELLOCCHI M. C., GORI C., D'ARRIGO R., MARCON L., BALOTTA C., ANTINORI A., D'ARMINIO MONFORTE A. and PERNO C. F., Identification of the minimal conserved structure of HIV-1 protease in the presence and absence of drug pressure, AIDS, 18 (2004) 11.
9. BROGLIA R. A. and TIANA G., Reading the three-dimensional structure of lattice model designed proteins from their amino acids sequence, Proteins, 45 (2001) 421.
10. TIANA G. and BROGLIA R. A., Folding and design of dimeric proteins, Proteins, 49 (2002) 82.
11. BROGLIA R. A., TIANA G., SUTTO L., PROVASI D. and SIMONA F., Design of HIV-l-PR inhibitors that do not create resistance: blocking the folding of single monomers, Protein Sci., 14 (2005) 2668.
12. BROGLIA R. A., PROVASI D., VASILE F., OTTOLINA G., LONGHI R. and TIANA G., A folding inhibitor of the HIV-1 protease, Proteins, 62 (2006) 928.
13. BROGLIA R. A., TIANA G., L. SUTTO L., PROVASI D. and PERELLI V., Low-throughput model design of protein folding inhibitors, Proteins, 67 (2007) 469.
14. JOHNSON V. A., BARLOW M. A. and MERRILL D. P. et al., Three-drug synergistic inhibition of HIV-1 replication in vitro by zidovudine, recombinant soluble CD4 and recombinant interferon-alpha A, J Infect. Dis., 161 (1990) 1059.
15. DULBECCO R., Endpoint methods - measurements of the infectious titer of a viral sample. In Virology, edited by DULBECCO R. and GINSBERG H. S. (Lippincott, Philadelphia, PA) 1998, pp. 22-5.
16. RUSCONI S., DE PASQUALE M. P. and MILAZZO L. et al., In vitro effects of continuous pressure with zidovudine (ZDV) and lamivudine on a ZDV-resistant HIV-1 isolate, AIDS, 11 (1997) 1406.
17. RUSCONI S., DE PASQUALE M. P. and MILAZZO L. et al., Loss of lamivudine resistance in a zidovudine and lamivudine dual-resistant human immunodefiency virus type 1 (HIV-1) isolate after discontinuation of in vitro lamivudine drug pressure, Antiviral Therapy, 3 (1998) 203.
18. NÉMETHY G. and SCHERAGA H. A., Biopolymers, 23 (1984) 2781; 581 (Erratum).
19. NÉMETHY G. and SCHERAGA H. A., Biochemistry, 25 (1986) 3184.
20. NÉMETHY G. and SCHERAGA H. A., Biopolymers, 28 (1989) 1573.
21. VITAGLIANO L., NÉMETHY G., ZAGARI A. and SCHERAGA H. A., Biochemistry, 32 (1993) 7354.
22. ZAGARI A., PALMER K., GIBSON K. D., NEMETHY G. and SCHERAGA H. A., Biopolymers, 34 (1994) 51.
23. VITAGLIANO L., NEMETHY G., ZAGARI A. and SCHERAGA H. A., J. Mol. Biol, 247 (1995) 69.
24. PATERLINI M. G., NEMETHY G. and SCHERAGA H. A., Biopolymers, 35 (1995) 607.
25. LEE J., SCHERAGA H. A. and RACKOVSKY S., Biopolymers, 40 (1996) 595.
26. RIPOLL D. R. and SCHERAGA H. A., Biopolymers, 27 (1988) 1283.
27. RIPOLL D. R. and SCHERAGA H. A., J. Protein Chem., 8 (1989) 263.
28. OOI T., OOBATAKE M., NÉMETHY G. and SCHERAGA H. A., Proc. Natl. Acad. Sci. U.S.A., 84 (1987) 3086; 6015 (Erratum).
29. VILA J., WILLIAMS R. L., VASQUEZ M. and SCHERAGA H. A., Proteins: Struct., Function, and Genetics, 10 (1991) 199.
30. RIPOLL D. R., VILA J. A. and SCHERAGA H. A., J. Mol. Biol, 339 (2004) 915.
31. VILA J. A., RIPOLL D. R. and SCHERAGA H. A., Proc. Natl. Acad. Sci. U.S.A, 100 (2003) 14812.
32. SCHERAGA H. A., LIWO A., OLDZIEJ S., CZAPLEWSKI C., PILLARDY J., RIPOLL D. R., VILA J. A., KAZMIERKIEWICZ R., SAUNDERS J. A., ARNAUTOVA Y. A., JAGIELSKI A., CHINCHIO M. and NANIAS M., Front. Biosci., 9 (2004) 3296.
33. SCHERAGA H. A., PILLARDY J., LIWO A., LEE J., CZAPLEWSKI C., RIPOLL D. R., WEDEMEYER W. J. and ARNAUTOVA Y. A., J. Comput. Chem., 23 (2002) 28.
34. LIWO A., OLDZIEJ S., PINCUS M. R., WAWAK R. J., RACKOVSKY S. and SCHERAGA H. A., J. Comput. Chem., 18 (1997) 849.
35. LIWO A., PINCUS M. R., WAWAK R. J., RACKOVSKY S., OLDZIEJ S. and SCHERAGA H. A., J. Comput. Chem., 18 (1997) 874.
36. LIWO A., KAZMIERKIEWICZ R., CZAPLEWSKI C, GROTH. M., OLDZIEJ S., WAWAK R. J., RACKOVSKY S., PINCUS M. R. and SCHERAGA H. A., J. Comput. Chem., 19 (1998) 259.
37. PILLARDY J., CZAPLEWSKI C, LIWO A., LEE J., RIPOLL D. R., KAZMIERKIEWICZ R., OLDZIEJ S., WEDEMEYER W. J., GIBSON K. D., ARNAUTOVA Y. A., SAUNDERS J., YE Y.-J. and SCHERAGA H. A., Proc. Natl. Acad. Sci. U.S.A., 98 (2001) 2329.
38. LIWO A., CZAPLEWSKI C, PILLARDY J. and SCHERAGA H. A., J. Chem. Phys., 115 (2001) 2323.
39. PILLARDY J., CZAPLEWSKI C, LIWO A., WEDEMEYER W. J., LEE J., RIPOLL D. R., ARLUKOWICZ P., OLDZIEJ S., ARNAUTOVA Y. A. and SCHERAGA H. A., J. Phys. Chem. B, 105 (2001) 7299.
40. LIWO A. ARLUKOWICZ P., CZAPLEWSKI C, OLDZIEJ S., PILLARDY J. and SCHERAGA H. A., Proc. Natl. Acad. Sci. U.S.A., 99 (2002) 1937.
41. OLDZIEJ S., KOZLOWSKA U., LIWO A. and SCHERAGA H. A., J. Phys. Chem. A, 107 (2003) 8035.
42. MAKSIMIAK K., RODZIEWICZ-MOTOWIDLO S., CZAPLEWSKI C., LIWO A. and SCHERAGA H. A., J. Phys. Chem. B, 107 (2003) 13496.
43. CZAPLEWSKI C, OLDZIEJ S., LIWO A. and SCHERAGA H. A., Protein Eng., Design & Selection, 17 (2004) 29.
44. LIWO A., OLDZIEJ S., CZAPLEWSKI C, KOSLOWSKA U. and SCHERAGA H. A., J. Phys. Chem. B, 108 (2004) 9421.